open access
Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity
Affiliations- Department of Neurology, Medical University of Warsaw, 8 Kondratowicza str, 03-242 Warsaw, Poland
- Department of Immunology, Biochemistry and Nutrition, Medical University of Warsaw, Poland
open access
Abstract
To assess interleukin 15 (IL-15) serum levels in patients with seropositive myasthenia gravis (MG); searching for potential relationship between IL-15 levels and clinical features such as gender, age at onset, clinical presentation or treatment received.
BackgroundIL-15 plays pivotal role in T-cell dependent autoimmunity. Increased IL-15 serum levels have been reported in several autoimmune diseases including MG patients from Japan.
Patients and methodsSera of 42 seropositive MG patients (66.7% women), mean age 50.6±23.7 years) have been tested by ELISA for IL-15 levels.
ResultsThere were no statistically significant differences between IL-15 serum levels in MG patients in comparison with controls as well as between subgroups of MG patients (early vs. late onset and thymoma MG). Mean/median IL-15 serum levels were similar in MG patients treated with corticosteroids (CS) and CS naïve. Outliers (very high values) were seen only in untreated generalized MG patients.
ConclusionsSerum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity.
Abstract
To assess interleukin 15 (IL-15) serum levels in patients with seropositive myasthenia gravis (MG); searching for potential relationship between IL-15 levels and clinical features such as gender, age at onset, clinical presentation or treatment received.
BackgroundIL-15 plays pivotal role in T-cell dependent autoimmunity. Increased IL-15 serum levels have been reported in several autoimmune diseases including MG patients from Japan.
Patients and methodsSera of 42 seropositive MG patients (66.7% women), mean age 50.6±23.7 years) have been tested by ELISA for IL-15 levels.
ResultsThere were no statistically significant differences between IL-15 serum levels in MG patients in comparison with controls as well as between subgroups of MG patients (early vs. late onset and thymoma MG). Mean/median IL-15 serum levels were similar in MG patients treated with corticosteroids (CS) and CS naïve. Outliers (very high values) were seen only in untreated generalized MG patients.
ConclusionsSerum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity.
Keywords
Myasthenia gravis, Interleukin 15, Cytokine, Autoimmune disease
About this articleTitle
Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity
Journal
Neurologia i Neurochirurgia Polska
Issue
Pages
364-367
Published online
2018-01-06
Page views
309
Article views/downloads
336
DOI
10.1016/j.pjnns.2017.12.011
Bibliographic record
Neurol Neurochir Pol 2018;52(3):364-367.
Keywords
Myasthenia gravis
Interleukin 15
Cytokine
Autoimmune disease
Authors
Ewa Sobieszczuk
Justyna Kubiszewska
Marta Lipowska
Piotr Szczudlik
Beata Szyluk
Małgorzata Dutkiewicz
Anna Kostera-Pruszczyk
